Rajeev
Saggar,
M.D.
Chief Medical Officer
Rajeev Saggar, M.D. joined Liquidia in 2022 where he serves as the company’s Chief Medical Officer. He brings more than 20 years of experience as a practicing pulmonologist to his role at Liquidia where he oversees all aspects of research, clinical development, medical affairs and regulatory affairs. Previously, Rajeev served as Vice President of Clinical Development at Theravance Biopharma with oversight of all phases of clinical development across its respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD and COVID-19. Prior to this, he served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix, and as the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix. Rajeev also served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. He has authored more than 60 peer-reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Rajeev holds a Doctor of Medicine degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.
Rajeev Saggar, M.D. joined Liquidia in 2022 where he serves as the company’s Chief Medical Officer. He brings more than 20 years of experience as a practicing pulmonologist to his role at Liquidia where he oversees all aspects of research, clinical development, medical affairs and regulatory affairs. Previously, Rajeev served as Vice President of Clinical Development at Theravance Biopharma with oversight of all phases of clinical development across its respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD and COVID-19. Prior to this, he served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix, and as the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix. Rajeev also served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. He has authored more than 60 peer-reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Rajeev holds a Doctor of Medicine degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.